Rocket One Inc.
RKTO evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $17.3M
- Lead Asset:
- biolexa (Phase 1)
What it means
What to watch
Prepared research question
What matters most for RKTO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RKTO
Rocket One Inc. (RKTO) is a clinical-stage biopharmaceutical company developing therapies for oncology, dermatology, and metabolic conditions, with a lead program in HT-001 for EGFR inhibitor-associated skin toxicities.
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$17.3M
Cash Runway
—
Lead Asset
biolexa (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Rocket One Inc..
Rocket One Inc. (RKTO) is a clinical-stage biopharmaceutical company developing therapies for oncology, dermatology, and metabolic conditions, with a lead program in HT-001 for EGFR inhibitor-associated skin toxicities.
- Cash & equivalents of $7.9M as of 2026-06-30 [sec]
- Net income of -$3.8M as of 2026-06-30 [sec]
- Shareholders' equity of $8.2M as of 2026-06-30 [sec]
- Lead program HT-001 is in a Phase 2a clinical trial (CLEER-001) for skin toxicities from EGFR inhibitors [news · 2026-02-25]
- HT-001 has received orphan designation and achieved a European regulatory milestone for multi-country site activation [news · 2026-01-15]
What works
- HT-001 Phase 2a trial is expanding with new clinical sites due to surging patient demand, reflecting compelling early results [news · 2026-02-25]
- The company has achieved a major European regulatory milestone for HT-001, enabling multi-country site activation [news · 2026-01-15]
- Pipeline includes multiple programs (HT-001, HT-KIT, HT-ALZ, GDNF metabolic) and a treasury reserve strategy with Bitcoin, Ethereum, and Solana [news · 2025-09-16]
What to weigh
- Net loss of $3.8M as of 2026-06-30 indicates ongoing cash burn [sec]
- Cash position of $7.9M as of 2026-06-30 may limit runway if revenue does not materialize [sec]
- The company is clinical-stage with no approved products, relying on successful trial outcomes and financing [news · 2026-02-05]
From the filings
Quoted directly from source documents.
HT-001 Phase 2a trial expansion due to patient demand
“Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites”
News · February 25, 2026
European regulatory milestone for HT-001
“Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European regulatory milestone for its HT-001 clinical program targeting cancer patients undergoing EGFR inhibitor therapies.”
News · January 15, 2026
Catalyst timeline
- 2023-07-19 · Phase 2a start for HT-001 — A randomized, placebo-controlled Phase 2a dose-ranging study for topical HT-001 treating skin toxicities from EGFR inhibitors.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Net loss of $3.8M as of 2026-06-30 with $7.9M cash may limit operational runway [sec]
- Clinical-stage dependency — No approved products; success hinges on Phase 2a outcomes and financing [news · 2026-02-05]
- Regulatory and trial execution risk — Multi-country site activation and trial enrollment depend on regulatory approvals and patient recruitment [news · 2026-01-15]
What to watch
- HT-001 Phase 2a CLEER-001 trial enrollment progress and interim data [news · 2026-02-25]
- European site activation and regulatory decisions for HT-001 [news · 2026-01-15]
- Pipeline updates for HT-KIT, HT-ALZ, and GDNF metabolic program [news · 2025-12-04]
- Financial reports and cash runway updates in upcoming SEC filings [sec_mda · as of 2026-08-14]
Sources: Catalysts · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Rocket One Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rocket One Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.17 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 21, 2026- % of float
- 4.8%
- Days to cover
- 1.9
- Shares short
- 749,807
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RKTO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rocket One Inc.?
Rocket One Inc. (RKTO) is a clinical-stage biopharmaceutical company developing therapies for oncology, dermatology, and metabolic conditions, with a lead program in HT-001 for EGFR inhibitor-associated skin toxicities.
What is Rocket One Inc.'s lead drug candidate?
Rocket One Inc.'s most advanced tracked candidate is biolexa (Phase 1) for atopic dermatitis (eczema).
Who is the CEO of Rocket One Inc.?
Mr. Robb Knie is the chief executive officer of Rocket One Inc. (RKTO).
Where is Rocket One Inc. headquartered?
Rocket One Inc. (RKTO) is headquartered in Hoboken, NJ, United States.
What therapeutic areas does Rocket One Inc. focus on?
Rocket One Inc. develops therapies across Neurology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.